S

Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250

Watchlist Manager
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Watchlist
Price: 104 000 KRW -0.76% Market Closed
Market Cap: 2.4T KRW
Have any thoughts about
Sam Chun Dang Pharm Co Ltd?
Write Note

Sam Chun Dang Pharm Co Ltd
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sam Chun Dang Pharm Co Ltd
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Long-Term Investments
â‚©30.5B
CAGR 3-Years
-17%
CAGR 5-Years
-1%
CAGR 10-Years
10%
Yuhan Corp
KRX:000100
Long-Term Investments
â‚©626.5B
CAGR 3-Years
-7%
CAGR 5-Years
0%
CAGR 10-Years
1%
SK Biopharmaceuticals Co Ltd
KRX:326030
Long-Term Investments
â‚©104.1B
CAGR 3-Years
148%
CAGR 5-Years
583%
CAGR 10-Years
N/A
Hanmi Science Co Ltd
KRX:008930
Long-Term Investments
â‚©833.5B
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
6%
Hanmi Pharm Co Ltd
KRX:128940
Long-Term Investments
â‚©159.2B
CAGR 3-Years
41%
CAGR 5-Years
11%
CAGR 10-Years
8%
C
Celltrion Pharm Inc
KOSDAQ:068760
Long-Term Investments
â‚©230.5m
CAGR 3-Years
-37%
CAGR 5-Years
-32%
CAGR 10-Years
-16%
No Stocks Found

Sam Chun Dang Pharm Co Ltd
Glance View

Market Cap
2.4T KRW
Industry
Pharmaceuticals

SAM CHUN DANG PHARM Co., Ltd. engages in the manufacture of pharmaceuticals. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2000-10-04. CO., LTD is a Korea-based company mainly engaged in the manufacture of prescription medicines. The Company’s products portfolio consists of antibiotics used for treatment of sepsis, respiratory diseases and others; circulatory disease medicines including cardiovascular and endocrine medicaments used for treatment of diabetes, hypertension, angina and others under the brand names of Glilazide and Atenolol; digestive medicines used for treatment of duodenal ulcer, gastritis and others; ophthalmological agents used for treatment of conjunctivitis, keratitis and other eye inflammation under the brand names of Ofus and Toracin, and anti-inflammatories used to release postoperative pains under the brand name Barotase and others.

Intrinsic Value
11 241.66 KRW
Overvaluation 89%
Intrinsic Value
Price
S

See Also

What is Sam Chun Dang Pharm Co Ltd's Long-Term Investments?
Long-Term Investments
30.5B KRW

Based on the financial report for Sep 30, 2024, Sam Chun Dang Pharm Co Ltd's Long-Term Investments amounts to 30.5B KRW.

What is Sam Chun Dang Pharm Co Ltd's Long-Term Investments growth rate?
Long-Term Investments CAGR 10Y
10%

Over the last year, the Long-Term Investments growth was -3%. The average annual Long-Term Investments growth rates for Sam Chun Dang Pharm Co Ltd have been -17% over the past three years , -1% over the past five years , and 10% over the past ten years .

Back to Top